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Abstract 
   In comparison to the policy for other field, the policy for medicine and public health is to 
consider the value of life or the value of the quality of life. Quality of life is very well known as a 
concept of QOL. Also, Quality Adjusted Life of Years (QALY) which integrates QOL over life of 
years is widely used as a measure of the value of life. Cost-effectiveness analysis for medicine 
and public health adopts two approaches to incorporate value of QOL or QALY. We summarize 
those advantage and disadvantage briefly at first. Unfortunately, cost-effectiveness analysis has 
not been committed and operated as an official rule for the method of policy evaluation for 
medicine or public health in Japan, yet. Thus we show some researches about it which examines 
ex post or ex ante policy evaluation using cost-effectiveness analysis. In other countries, some 
political decision making in medicine or public health is based on cost-effectiveness analysis. 
However, the pressure of the financial deficit will require more accountability about evidence. 
Therefore, cost-effectiveness analysis must be more important even in political decision making 
in medicine or public health in Japan. 
 
   
 
I.  Some Features of Cost-Effectiveness Analysis in Policy for Medicine or 
Public Health 
 
   It is a well known fact that cost-effectiveness analysis is a basic tool for policy evaluation 
even in Japan as in this issue. This paper focuses on policy for medicine or public health and 
summarize and discuss about cost-effectiveness analysis. 
   Nevertheless, the policy for medicine or public health share the same grounds with other 46  Y. Ohkusa, T. Sugawara / Public Policy Review 
public policy such as road construction, agriculture or defense. It needs an enormous cost which 
is financed mainly by tax or premium other than copayment. On the other hand, the policy for 
medicine or public health has inherent features. Namely the policy for medicine or public health 
is closely related with life and its quality. Of course, other policies may take life and its quality 
into consideration. For instance, the policy for highway construction must evaluate death or 
disability due to traffic accidents as its negative benefit or cost, or the policy for the airport 
construction must cost health problem by noise pollution. However, life and its quality is 
definitely the most important issue for evaluation of medicine or public health. 
      Then how should we evaluate life and its quality and how do we take it into 
cost-effectiveness analysis. This is the important feature in cost-effectiveness analysis of the 
policy for medicine or public health. At first, we have to evaluate life and its quality numerically. 
Unless we evaluate it numerically, we cannot compare the quality of life of appendicitis patients 
and patients suffering from heart attacks. It is very important and it is a big issue in health 
economics, but it is not well known in other fields of economics, and thus we discuss it at first. 
   Then we have to use this numerical evaluation of life and its quality for political decision 
making. There are mainly two types of methods. One method is direct monetary evaluation of life 
and its quality. This method ignores the features of life and its quality and treats them as other 
goods. Thus we can apply the cost benefit analysis as other fields in economics other than 
medical or public health do, and we can compare medical or public health to highway 
construction, environmental policy and so on. 
      Another method is to avoid direct monetary evaluation for life or its quality, and use another 
unit other than monetary unit. Thus we can not compare the evaluation by this method with 
other fields since it emphasizes the specialty in medical and public health. Below, we explain 
briefly three features of cost-effectiveness analysis in the policy for medicine or public health, 
and then show its applications. 
 
II.    Numeral Evaluation for Life and Its Quality 
 
   C o s t -effectiveness analysis in policy for medicine or public health sometimes evaluates life 
and its quality numerically (QOL). QOL measures severity of illness or disability which defines 
death as zero and perfect health as one. There are several ways to measure QOL such as 
EuroQoL(Brooks(1996)), SF36(Ware and Sherbourne(1992)), and HUI(Le, Buron, Costet, 
Rosman and Slama(2002)). These methods measure the total situation of health and apply to 
general health people in addition to all kinds of illness or disability in principle. On the other 
hand, disease specific measures are also well developed. For example,Q-tility(Weeks et 
al(1994)), FLIC(Functional Living Index-Cancer), CARES(Cancer Rehabilitation Evaluation 
System) measures the QOL of cancer patients, and DQOL(Diabetes Quality of Life Measure) is 
for diabetes.   Y. Ohkusa, T. Sugawara / Public Policy Review 47 
      QOL is measured by question are and it asks the individual's physical, psychological and/or 
social function as several attributes. For example, Euro QoL has five attributes such as moving, 
usual activity, self care, anxiety/depression, and pain. On the other hand, SF36 has 36 attributes. 
Each attributes has three to five levels and the respondents select one level. 
      These measurements aim to evaluate QOL in total. Conversely, QOL in specific condition is 
measured by mainly Standard Gamble (SG), Time-Trade Off (TTO), or Rating Scale (RS). SG 
asks the probability of being in perfect health (QOL=1) and otherwise die (QOL=0) if 
intervention is implemented which intervention and no-intervention are indifferent as Figure 1 
and following trivial equation 
QOL in a situation = pQOL in perfect health + (1- p)QOL in death = p (1) 
based on the expected utility theorem which is very well known in economics. SG has a firm 
foundation in economics and it is the best way to measure QOL, but it seems to be very difficult 
to understand for the respondents. 
 









      On the other hand, TTO asks years of perfect health which indifferent with a fixed years (say, 
10 years) under a situation as shown in Figure 2. Since the equation 
QOL under a situation × t = QOL under perfect health × x = x  (2) 
is held and thus QOL under a situation is measured by x/t. This method also seems to be difficult 
as SG. 
      SG and TTO focus on one aspect of utility but ignore another aspect. Namely, SG focuses on 
the avoidance of uncertainty and thus it measures risk aversion. However, it lacks duration or 
time and thus it ignore time discount. Conversely, TTO compares two durations including time 
discount and ignores risk aversion. Therefore these two methods are not complete and we have 
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      RS measures QOL in a very simple way. Namely, it asks QOL directly as a point more than 0 
which corresponds to death, and less than 100, which corresponds to perfect health. Figure 3 
indicates an example of RS which uses a thermometer. This method is easy to understand and 
widely used. 
   The most widely used method to measure QOL is self-evaluation. This method is adopted 
internationally and has been used for a long time. In Japan, Comprehensive Survey Living 
Standard, which is a national survey and is used every three years. This survey asks "What is 
your current health condition ?" and asks the person to choose one choice of very good, good, fair, 
bad, and very bad. However it does not specify duration and reference group to compare it with. 
In other words, the meaning of "current" seems to be ambiguous. It may be this moment, today, 
or these days. Since it is also unclear whom to compare with, some one may compare their 
condition with others in the same age group or other people may compare with their own health 
in the past. Internationally, the question are clearly defines the duration to refer to as one year, 
half a year or one month, and asks them to compare their health with other people in the same 
age group(Van Doorslaer, Wagstaff, et al (1997)). 
      Since QOL measures instantaneously quality of life, it lacks the concept of duration. Thus we 





  β  
s
QOLt+s (3) 
where β the discount factor for discounting future conditions. It is well known and applied as 
Q u a l i t y  A d j u s t e d  L i f e  o f  Y e a r s  ( Q A L Y ) . T h e r e  i s  s o m e  c o n t r o v e r s y  s u r r o u n d i n g  t h e  d i s c o u n t  
factor. Namely it should be set as interest rate so far, but the insistence that health condition 
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      Sometimes QALY is called as utility in health economic literature. If the source of utility is 
only health, and utility is described as a linear function of health, QALY coincides with lifetime 
utility. However, if not. QALY and lifetime utility may diverge. We have to remind ourselves 
that term utility may be different from other fields of economics other than health economics. 
 
III.    Monetary Evaluation of Life and QOL 
 
   So as to achieve a more efficient distribution of medical resources and then to constrain 
unlimited increasing medical costs, cost effectiveness analyses has been introduced, especially in 
the approval or price setting of new drugs. This idea can be described by the following simple 
equation: 
ICER =  C1-C0     E1-E0
 <  µ   (4) 
where ICER is the incremental cost effectiveness ratio, C is cost and E is effectiveness 
represented by QALY. The subscript zero in the equation means traditional or currently 
standard drugs or treatments so far and new indicates a new drug or treatment. 
      It is well known, that this criterion has been already applied in Australia and the Canadian 
p r o v i n c e  o f  O n t a r i o .  T h o u g h  t h e r e  i s  n o  s u c h  m o v e m e n t  f o r  t h i s  i n  J a p a n ,  i t  n e e d s  t o  b e  
introduced in the near future. Thus, basic research about it is necessary for its introduction; or 
moreover for the argument in its favor and preparation for its introduction. 
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in the USA (Goldman et al(1992)), 20 thousand Canadian dollars in Canada (Laupacis et 
al(1992), 30 thousand pounds in the UK 
1), 36 thousand Australian dollars in Australia(George, 
Harris and Mitchell(2001)) and 30 thousand Euros in the Netherlands (Welte, Postma, Bos, van 
Alphen(2002)). However, the number itself is not so important; in fact, in Australia where this 
criterion is used in actual decision making for the approval of new drugs, an application is not 
accepted if the ICER is more than 69 thousand Australian dollars. Conversely, they never reject 
it if it is less than 18 thousand Australian dollars. Similarly in the UK, NICE accepted riluzole, a 
drug to treat people with motor neuron disease, even though its ICER was more than 40 
thousand pounds. However even though it has some ranges, there is not any concrete foundation 
to decide the criterion and its range; it is usually based on "expert opinion." 
     On the other hand, there is an alternative idea for deciding the number µ from the point of 
view of human capital or foregone income. This idea is typically used in compensation for loss in 
court, or as a premium in wages for risky jobs. Tolley, Kenkel and Fabian(1994) survey the 
empirical research regarding this and find that it ranges from 70 to 175 thousand US dollars. In 
particular, Cutler and Richardson(1997) employ 100 thousand US dollars. 
   In principle, however, this number must be decided by the preference of the general 
population, who are sovereign in a democratic society. The "expert opinion" of a few experts like 
Goldman might not be appropriate to decide it. Hence, we need a social survey to discover the 
number in a given society. 
   This paper undertakes such a survey and analyses its distribution and characteristics. 
Especially, we consider whether a method based on human capital or foregone income is 
appropriate. As mentioned before, there is no previous research to decide this critical value from 
a survey of the general population survey. Therefore this paper should contribute to this field. 
 
III.1.  Data 
 
      The data set used in this paper is based on a survey carried out in March 2002 in Japan. This 
survey was implemented through a research company with which the sample households 
contracted. The households were randomly selected. However, the research contract might yield 
a sample selection bias and thus some caution is needed in estimations and interpretations. The 
number of surveys distributed was 900, of which 783 were returned. We use 1119 individuals for 
our analysis. 
   The  questionnaire  about  µ was as follows; 
      Let's assume that there is a patient who in their current situation will die today. However, a 
new treatment can extend her/his life for one year in perfect health. What amount should 
society pay for this new treatment?    Please write a particular number. 
                                                                            
1)    The number in UK is according to http://bmj.com/cgi/reprint/323/7325/1324/a.pdf.   Y. Ohkusa, T. Sugawara / Public Policy Review 51 
      The response field is constructed to represent from 0 to 100 million yen. 
III.2.  Summary  Statistics 
 
   Summary statistics are summarized in Table 1. Though the average µ is 6.29 million yen 
(50.32 thousand US dollars), the standard deviation is so huge (18.12 million yen) and the 
median is only one million yen (8 thousand US dollars). 
 
Table 1: Summary Statistics 
  Average  Std. Dev.  Minimum  Maximum 
µ  628.9751  1812.207  0  9999 
Age  44.37182  19.49136  13  99 
Female Dummy  .5294118  .4993011  0  11 
Household Income  700.3255  410.6517  0  3250 
Financial Net Asset  -136.0333  1468.617  -4500  4450 
Real Asset  .8254805  .3796145  0  1 
Note:Real asset is dummy variable for whether they have own their house or live in rental house. Unit for µ, 
household income and financial net asset is ten thousand yen (eighty dollars). Sample size is 1119. 
 
   S i n c e   µ is heavily skewed, some results may be dependent on whether we use its average or 
median as the representative number. If we more or less suppose a democratic decision making 
process, we have to use the median. In the following analysis, we are reminded of such a skewed 
ness in the distribution of µ. 
      Figures 1 to 6 illustrate the distribution according to some characteristics of the respondents. 
In these figures, the horizontal axis measures the log of µ and the vertical axis indicates the 
frequency by Kernel density estimation. Figure 1 shows the whole distribution and we can see 
its peak is around five, which is about 1.5 million yen (12 thousand US dollars). The distribution 
by age (less than 65 years old, or more than), gender, income (less than average, or greater than), 
net financial assets (less than average or greater than), and real assets (whether they have their 
own residence, or they live in a rented accommodation) are illustrated in Figures 2 to 6. It can be 
seen that the elderly evaluate µ more than the younger, males have a greater concentration 
around peaks, and the peak in higher income or asset households is higher or moves to an upper 




      To confirm the intuition from these figures, some estimations are performed as follows. The 
dependent is the log of µ, which is the same in the figures. The explanatory variables are age, 52  Y. Ohkusa, T. Sugawara / Public Policy Review 
gender, household income, and net financial and real assets. 
      We adopt two estimation methods, the interval method and the quintile method, to take into 
account these features of the characteristics on the distribution. The former is basically a linear 
estimation that represents the average of the distribution in some situations. However, it treats 
that a zero or a more than 100 billion yen response indicate a negative or more than 100 million 
yen, because the response field is not constructed to represent negative or more than 100 million 
yen. Never-the-less, this estimation is linear for the responses which are more than zero and 
less than 100 million yen. Conversely, the latter estimation procedure focuses on their median in 
some situations. As emphasized before, the median is the important characteristic in a 
democratic society, and it reduces extremely high responses to a level for evaluation, which is 
confirmed in the figures; a comparison with the linear model including the former estimation. 
      The estimation results are summarized in Table 2. The estimation results are similar in each 
of the tables. Namely, for every one year older, µ declines by 1.3 to 2.2%. This age effect seems to 
be large. If we add the quadratic term of age as an explanatory variable, it is not significant, 
which is not shown in the tables. Hence, µ decreases monotonically due to age.   
 
Table 2: Estimation Results 
  Interval regression  Quantile regression 
  Coefficients  p-value  Coefficients  p-value 
Age  -0.0222687  0.057  -0.0130291 0.000 
Female Dummy  -0.1083792  0.629  -0.1064494 0.168 
Household Income  0.2793647  0.010  0.2367467 0.000 
Financial Net Asset  -0.0000312  0.684  0.0000149 0.574 
Real Asset  -0.4822878  0.120  -0.1319622 0.217 
Constant  3.231015  0.000  3.726981  0.000 
log likelihood  -2371.7455     
pseudo R
2      0.0021 
p-value for Wald test  0.0033     
Note:The null hypothesis in Wald test is that all coefficients except for constant term are zero. 
 
   The coefficients of household income are significantly positive and the elasticity is 0.24 to 
0.28. In other words, increasing income causes µ to rise, but it is not responsive. If µ is based on 
human capital or foregone income like Tolley, Kenkel and Fabian(1994) or Cutler and 
Richardson(1997), since these are proportional to current income after controlling age, the 
elasticity should be one. However, χ
2 statistics on the interval estimation is 44.36, and F 
statistics on the quartile estimation is 395.19 for the null hypothesis that the elasticity is one 
and that these probabilities are far less than 0.01%. Therefore, we can reject the null hypothesis 
and so not calculate µ based on human capital or foregone income.   Y. Ohkusa, T. Sugawara / Public Policy Review 53 
III.4.  Discussion 
 
   µ : the critical value of expenditure per QALY which a society can tolerate or accommodate, 
gives some standard for  effectiveness regarding  medical services. Cutler and Richardson 
(1997) use 100 thousand US dollars as µ and argue its effectiveness for medical services. 
   However, there is some confusion involved in this idea because 100 thousand US dollars is 
calculated based on foregone income, and thus it may be the value of life, but it is not an upper 
limit which the society tolerate for medical services 
2) 
      In reality, medical services must be allocated a value less than that of a life in their optimal 
resource allocation. It should not be optimal that all resources are allocated to medical services 
and nothing to other activities such as consumption and leisure. 
   Moreover these differences between the critical value of expenditure per QALY which the 
society can tolerate and the value of a life could reflect the difference between WTP and WTA, 
which is well known in empirical research. In general, WTA tends to be larger than WTP in a 
similar situation (Horowitz and McConnell(2002), Walton, Graves, Mueser and Johnson, Fries, 
and Banzhaf(2002), Salkeld, Randy, and Short(2000), Hanemann(1991)). In this context, the 
value of a life is WTA, which amounts to accepting death, and the expenditure per QALY which 
a society can tolerate, of course, is WTP. Therefore, it is somewhat natural that the latter is far 
less than the former. 
   In addition to these rather logical arguments, we add some evidence of differences from 
empirical investigations from a general population. As emphasized before, since the income 
elasticity of µ is significantly less than one, such a difference is very important even in a theme of 
economic sense. Therefore, we have to use one million yen as the median or 600 million yen as an 
average as for µ in Japan. 
   Conversely, since we confirm that µ has quite a skewed distribution, the characteristics of 
the distribution, such as an average or even a median, seem to be meaningless. Hence the 
criterion of cost effectiveness analysis in eq.(1) should change to 
Prob   C1-C0     E1-E0
 <  µ(i)  > α (5) 
Where µ(i) is µ for the i th person. 
 
III.5. Further Research 
 
   This paper considers that the critical value of expenditure per QALY that a society can 
tolerate is the most important parameter in the cost effectiveness analysis. As a result, its 
                                                                            
2)    Another problem in Cutler and Richardson (1997) is whether the extension of life expectancy is due to 
medical services. This dubious assumption is imposed implicitly, but it might be too simple. At least, 
some contribution from improvements in nutrition and/or a great development in the public health 
services needs to be taken into account. 54  Y. Ohkusa, T. Sugawara / Public Policy Review 
average is six million yen (48 thousand US dollars) but its median is just one million yen (eight 
thousand US dollars), and thus it has a very skewed distribution. Additionally, age and 
household income affect it significantly. 
     However, there are many unsolved problems remaining in this paper. First, the questioning 
procedure has some faults. As explained, the amount was asked directly, but this procedure is 
frequently misleading, resulting in some extreme responses and a high correlation with income 
(Donaldson, Brich and Gafini(2002)). In fact, an improved procedure has already been 
suggested; recently conjoint analyses have been widely applied to this field. If applied here, the 
significant correlation between µ and income could disappear. 
      Moreover, there may be a problem in that a question in the survey includes reference to any 
other social cost other than medical costs. To confirm that possible effect, we need to perform a 
comparison survey limited to medical costs. It should be noted that such costs are sometimes 
included in the analyses of the cost-effectiveness from a societal view point. For instance, the 
cost for nursing care, long term care or cost of lost opportunity by the family care giver. Hence, 
incorporation of these costs is appropriate from a societal point of view. 
   Finally, it appears to be inappropriate that the question is asked only about two reference 
points, i.e. perfect health status and death. If we used some intermediate status, we could define 
µ at a marginal rather than in an average like eq. (1), and thus we could define it based on QOL 
levels. However, such an intermediate status needs a QOL evaluation for it. This implies adding 
more unknown parameters into the analysis, and it would make the survey far more complex. 
Though this paper avoided this complexity by using just two polar cases; a future survey might 
be able to solve this problem. 
      Research regarding a critical value of expenditure per QALY which a society can tolerate, or 
accommodate, has just started; more following such research is necessary. Following research 
projects should find more reliable parameters for the distribution, and by this it would possibly 
confirm the robustness of our results. 
 
IV.  Non-Monetary Evaluation of Life and QOL 
 
   We sometimes face an emotional contradiction to a monetary evaluation of life or QALY. 
Moreover there is no strong evidence in its value except for Japan. Hence it has not yet reached 
an agreement in academic and consensus in public sentiment. So as to avoid such a situation, life 
or QALY are often evaluated by non-monetary units in the medical and public health field. For 
instance, cost-effectiveness analysis evaluates life as a time unit or outcome as a physical unit 
other than QOL, and cost-utility analysis use QALY itself as an outcome measure.   Y. Ohkusa, T. Sugawara / Public Policy Review 55 
IV.1.  Cost-Effectiveness Analysis in Narrow Sense 
 
      The physical units which measure the outcome in cost-effectiveness analysis are test result 
such as blood pressure, blood sugar and so on, or survival rate and life expectancy. Especially, it 
is so called cost-effectiveness analysis in a narrow sense which means the effectiveness is 
defined by only physical units. Meanwhile cost-effectiveness analysis in a broad sense includes 
any definition of effectiveness such as monetary or utility units. Physical units are widely used 
in the studies in medicine. For example, clinical trial usually measures its outcome as a physical 
unit. In this sense, its accumulation of facts is enormous. We can use such results to investigate 
in cost-effectiveness analysis, and thus it is the most advantageous of it. If we can get the 
information about cost, we can combine them and obtain the consequence of cost-effectiveness. 
This method, which means to get the data of outcome and cost separately, is so called scenario 
study, and it is the most widely used in cost-effectiveness analysis in a broad sense. However, 
we have to remind ourselves that usually cost and effectiveness are correlated, particularly 
negative correlated, and thus the synergic study has bias. 
 
IV.2.  Cost-Utility Analysis 
 
      QALY is used as outcome measure in cost-utility analysis which has advantage in integration 
with QOL and life of years. The most important shortcoming in cost-effectiveness analysis is 
that a little improvement in the test result may not affect QOL or life of years. For example, 
antihypertensive drug can reduce blood pressure, but patients cannot feel to improve heartthrob 
comparison with the past, QOL must not be developed. In other words, it must be meaningless if 
such a drug or treatment cannot raise QOL. In this sense, cost-utility analysis is based on the 
patients' perspective, instead of the doctors' perspective in cost-effectiveness analysis in a 
narrow sense. 
      On the other hand, the most important weakness in cost-utility analysis is difficulty in the 
estimation of QOL and even expected life of year. As explained before, it is usual that the 
measurement of QOL itself is difficult and typically it has a wide variety in its distribution. 
Moreover, concerning life expectancy, studies which have a long observation period, say ten 
years or more, are rare and thus survival rate is typically is used as a proxy of it. Due to these 
problems, cost-utility analysis is not applied as often as cost benefit analysis or 
cost-effectiveness analysis in a narrow sense. 
 
IV.3.  Statistical  Problem 
 
   As explained, cost and outcome have different units in cost-effectiveness analysis in a 
narrow sense and cost-utility analysis and thus we have to evaluate them as a ratio instead of 56  Y. Ohkusa, T. Sugawara / Public Policy Review 
net subtraction as we would a net benefit in cost benefit analysis. Ratio and subtraction seem to 
be similar, but there is a big difference statistically. Namely, since cost and outcome are assumed 
to follow certain types of distribution, typically normal distribution and thus the probability of 
that cost or outcome being zero may be more than zero, the distribution of ratio may not exist, 
even though the distribution of subtraction is always defined. It is not a rare case that the 
outcome is zero in the field of medicine or public health (Lothgren and Zethraus(2004),Willan 
and O'Brien(1999), Gardiner, Huebner, Jetton and Bradley(2000)) 
   So as to fix this problem, some methods are proposed. The most simple way is the delta 
method. It is well known in economics which Taylor expansion to ratio and linearized it, and 
then evaluate it approximately. However, nevertheless, linear approximation for ratio seems to 
be inaccurate. Thus this method usually is not applied to cost-effectiveness analysis. 
   Another method is the Fieller method (Willan and O'Brian(1996), Fieller(1954)) and it is a 
traditional method to test for ratio. It uses χ
2 distribution to test and thus it does not 
approximate the distribution, but it assumes a normal distribution for cost and outcome. These 
assumptions may not hold if cost or outcome does not follow the normal distribution. In 
particular, it is well known that cost has fatter tail than normal distribution. In that case, this 
method does not seem to be appropriate. 
      Recently, bootstrapping is often used so as to fix this problem. This method does not assume 
cost or outcome will follow certain types of distribution and thus it has advantages over the 
above two methods. Moreover, though the above two methods assume two distributions for cost 
and outcome and do not consider the distribution of its ration directly, bootstrapping can 
consider the distribution of a ratio directly. Therefore it is more accurate and appropriate for 
cost-effectiveness analysis in this sense. 
 
IV.4.  Fundamental  Problem 
 
   Let we get data cost and QOL or outcome which is measured by physical unit fortunately. 
Moreover, we can the get average or distribution of cost effectiveness ratio. For example, 
Wiiliam(1985) shows that so as to gain one more year of life, smoking cessation campaign needs 
170 ponds, pace maker require 699 ponds, femoral head and neck replacement surgery(752 
ponds),bypass surgery for non-severe angina pectoris(1042 ponds), control of blood-cholesterol 
level(1695 ponds), kidney transplantation(3030 ponds), screening of breast cancer (3448 ponds), 
heart transplantation(5000 ponds), bypass surgery for severe angina pectoris(12658 ponds), 
extracorporeal dialysis(14706 ponds). This list of cost-effectiveness ratio in each intervention is 
called a league table. Then how should we use this league table to actual decision making in 
medicine or public health. For example, which intervention should be implemented and which 
intervention should be rejected ? 
      In principle, it appears to be rational decision making to accept the intervention in order of   Y. Ohkusa, T. Sugawara / Public Policy Review 57 
small cost per one year of life gained or low cost-effectiveness ratio until the budget is 
exhausted. In the above example, we have to approve or cover by health insurance in  the 
following order; advertisement for smoking cessation, pace-maker, femoral head and neck 
replacement surgery, bypass surgery for non-severe angina pectoris, control of 
blood-cholesterol level, kidney transplantation, screening of breast cancer, heart 
transplantation, bypass surgery for severe angina pectoris, extracorporeal dialysis. In this case, 
dialysis in the hospital may not be covered by health insurance, and thus the total cost should be 
paid by the patient, even though the patient will die within a few days if they cannot use 
dialysis. 
   However, this idea seems to be too simple to implement. Namely, can we compare two 
treatments among different diseases? In the above example, CABG is certainly a higher cost per 
one year of life gained than a smoking cessation campaign, but the campaign cannot treat heart 
attacks. In other words, CABG and smoking cessation campaign cannot be substituted for each 
other, but we have to think of them independently even though they are both things in medicine 
or public health. Therefore, we must limit comparing the its cost effectiveness to substitutable 
drugs, treatments, or policies. 
      We have to remind ourselves of one more thing about policies for medicine or public health. 
That is that we always have status quo for drugs, treatments or policies even if it means we in 
fact "do nothing". Obviously, status quo and new drugs, treatments or policies are substitutable. 
Thus we have to compare these two alternatives and discuss which is better from the view point 
of cost effectiveness. ICER as mentioned in the previous section embodies this idea. If we do not 
have any particular drug, treatment or policy, we set C0=0, E0=0 and thus ICER is 
ICER =  C1-C0     E1-E0
 =  C1    E1
 (6) 
It goes back to being a simple cost-effectiveness ratio in the league table. 
   If a new drug, treatment or policy is more effective than E1>E0, but it is cheaper than the 
status quo C1<C0, we, of course, always have to adopt the new one. However, if E1>E0 but it is 
more expensive than C1>C0, then we need some criterion. In fact, we face this situation in almost 
all of cost-effectiveness analysis. If we adopt new alternative, ICER is less than criterion, and 
reject it otherwise. In the case of cost-utility analysis, since effectiveness is defined by QALY, 
this criterion is surely µ which we discussed in the previous section. Therefore, we can conclude 
that cost-utility analysis becomes cost-benefit analysis at the time of decision making. Even in 
the case of cost effectiveness analysis in narrow sense and effectiveness is defined by expected 
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V.  Application of Cost-Effectiveness Analysis to Policy for Medicine and 
Public Health in Japan 
 
   Unfortunately,  cost-effectiveness analysis has not been adopted in practice even in the case 
of approval of new drugs in Japan as mentioned before. Moreover, it also has not been declared 
formally for use it as a formula in other policy evaluation for medicine or public health. However, 
it does not mean that cost-effectiveness analysis is useless in policy evaluation for medicine or 
public health. In the near future, financial pressure, especially pressure for effective medicine, 
will play a key role in its decision making. If the new policy lacks a foundation in cost 
effectiveness, it will face strong opposition. Conversely, if a policy has strong evidence of 
cost-effectiveness but the government does not adopt it, the government will be condemned 
harshly due to their inaction. 
      A s  i n  o t h e r  p o l i c i e s ,  c o s t -effectiveness analysis was applied to some policies for medicine or 
public health so far, and some examples are shown in the following. The first example is 
application for a vaccination program and the second one is for a smoking cessation program. 
      Vaccination program is one of the most important issues in which cost-effectiveness analysis 
should be applied. Since it is expensive and it has some side effects, the scientific evaluation and 
comparison between its cost and benefit is key for both those for and against it. In other 
countries, cost-effectiveness analysis has played a key role in the decision making for 
vaccinations (Stratton, Durch, and Lawrence(2000)), but in Japan, it has just started. 
   We  show  cost-effectiveness analysis for subsidy of influenza vaccination for the elderly. In 
November 7, 2001, the vaccination law was reformed and it started to subsidize the influenza 
vaccination for the elderly. This policy should be confirmed by the cost-effectiveness 
perspectives because it costs very much. It was published originally as Ohkusa(2005). 
 
V.1.    Example 1:Policy Evaluation for the Subsidy of Influenza Vaccination for the Elderly 
 
V.1.1.  Material 
 
      The data about copayment of influenza vaccination, population, and shot rate of the elderly 
in the '01/'02 and '02/'03 seasons was surveyed by telephone interview to correspondents in the 
local governments of metropolitan and 12 other big cities in Japan. This survey was performed by 
the author. 
   The cost of the copayment is determined by these local governments every year, and the 
excess cost more than the copayment is subsidized by the central and local governments directly 
to the medical institutions. The total cost of the vaccination, which is charged by the medical 
institution to the elderly and local governments, is decided through negotiation between the 
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publicly. In other words, we can only know the copayment for each year and each city, while the 
total cost and thus the amount of the subsidy are unknown. In this sense, the total cost includes 
all components of items for the vaccination and the profit of medical institutions. 
   The mortality rate due to pneumonia or influenza was obtained from Vital Statistics of 
Population in 2002 and 2003. The data of total population was obtained from the National 
Population Census in 2000. 
 
V.1.2.  Method 
 
 (1)  Estimation 
 
      Estimation is performed with the following two parts. At first, we examine the impact of the 
variation of copayment on shot rate. Let Ri,t,  Ci,t, and Tt respectively denote shot rate and 
copayment in i area and t year, and year variable for '02/'03 season that captures the difference 
between sample seasons keeping constant all other aspects. The estimation equation is 
Ri,t =αi +αcCi,t +αtTt + εi,t   (7) 
The second part is to estimate the relationship between shot rate and mortality rate due to 
pneumonia or influenza. The estimation equation is 
Di,t =βi +βRRi,t +βtTt + υi,t   (8) 
where  Di,t is pneumonia and influenza mortality rate. Unfortunately, since pneumonia and 
influenza mortality rate of the elderly by area and season is not reported, we use the mortality 
rate of the total population irrelevant to the age. 
   The estimation method is weighted least square with the elderly population and the total 
population as a weight respectively in the first and the second estimation. 
   N o t e  t h a t  w e  h a v e  t o  r e m a r k  i f  εi,t and υi,t are correlated, the estimated coefficient βR 
certainly has bias. Moreover, the direction of bias may be positive or negative depending on 
E[εi,t,υi,t]. For example, an increase in the number of weak elderly persons residing in 
institutions, shot rate for these people usually is higher than elderly people living at home, and 
the mortality rate may still be higher due to their weakness even if the shot rate is the same. 
This correlation may lead to the upper bias in the coefficient. Conversely, the shot rate may 
represent the overall welfare spending or situation of the elderly in that area controlled out 
copayment. If this spending or situation improve the elderly health condition and reduce the 
mortality rate, this relationship make the lower bias in the coefficient. 
   In both cases, these are very well known as the simultaneous bias and we have to adopt a 
method that corrects such biases. The method, called instrumental variable method, uses the 
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rather than the observed raw Ri,t[1]. 
 
 (2)  Benefit-Cost Ratio 
 
   Using these estimation results, we can evaluate the policy by net benefit (NB) and 
benefit-cost ratio(BCR). NB is defined simply by the difference of benefit and cost due to the 
policy, and BCR is defined by its ratio. 
      NB can be calculated as follows. The perspective is of the society, and the time horizon is set 
to be one year because the effect of the vaccination is less than one year and the vaccination can 
extend their life one year at maximum. Due to the limited data, the effectiveness of the 
vaccination is limited to the prevention of death. The vaccination cost is defined as the sum of 
the copayment and subsidy, but the opportunity cost for the shot is not taken into consideration 
because they are typically retired. Moreover, the side effects of vaccination are also ignored for 
simplicity. 
      Vaccination cost is assumed to be 4.5 thousand yen (36 dollars), and the benefit of one year 
increase in life expectancy is assumed to be 6 million yen (48 thousand dollars).These numbers   
are widely used number in the US[2] and it is confirmed to be plausible even in Japan[3]. 
   T h e n   N B   i s  
 
Monetary value of avoidance in mortality by rising shot rate - Additional cost by rising 
shot rate 
= Rising shot rate due to subsidy×Reduction in mortality rate due to rising shot rate   
  ×6 million yen - Rising shot rate due to subsidy×4500 yen 
= 4000/3×Reduction in mortality rate due to rising shot rate  (9) 
 
Similarly, BCR is 
Monetary value of avoidance in mortality by rising shot rate
                       Additional cost by rising shot rate  
= 
rising shot rate due to subsidy×Reduction in mortality rate due to rising shot rate
                               Rising shot rate due to subsidy  
 ×
6 million yen
       4500 yen  
= 
4000×Reduction in mortality rate due to rising shot rate
                      3   (10) 
V.1.3.  Result 
 
 (1)  Estimation  Result 
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      The first and second columns in Table 4 show that the increase in copayments significantly 
reduces the shot rate. As its coefficient is -.007, since it means the shot rate would rise by .007 
percentage point in every 1 yen subsidy, if copayment is subsidized by 1000 yen (8), then the 
shot rate will rise by 7 percent points. Since the coefficient for '02/'03 season is significantly 
positive, the shot rate raised by 8.8 percent points in '02/'03 season compared with the '01/'02 
season where the other situations are completely the same. All area dummies, which indicate the 
difference from Sapporo, are insignificant. Since the degree of freedom adjusted R
2 is high, it fits 
quite well. 
      The third and fourth columns in Table 4 summarize the estimation results of crude weighted 
least square about mortality rate and they indicate that the shot rate negatively effects mortality 
rate but it is not significant. On the other hand, the fifth and sixth columns in Table 4 show the 
results for the instrument variable method. They show significant effect of shot rate on mortality 
rate and its estimated coefficient is -0.003, i.e. if the shot rate is raised by 10 percentage points, 
the mortality rate of pneumonia and influenza would decrease by .03 percentage point. 
 
  (2)    Net Benefit and Benefit Cost Ratio   
 
      Suppose the calculation of the net benefit and BCR of the policy change which raise 1000 yen 
(8) in subsidy. At first, this policy would increase the shot rate by 7 percentage points as 
mentioned above and this reduces the mortality rate of the would population by .0196(=7×
0.0028) percentage points. It means to avoid 23520 (=.000196×120 million) death. This benefit 
can be evaluated as 141.2 billion yen (1.13 billion dollars) (=23520×6 million yen) if the value of 
life is assumed to be 6 million yen or 50 thousand dollars. 
     On the other hand, the additional cost of this policy change must   be the product of the 7 
percent points rise in the shot rate, 4500 yen (cost of vaccination in social per one elderly) and 
20 million (population of the elderly). It expends 6.3 billion yen or 50.4 million dollars. 
Therefore the net benefit must be the difference of benefit and cost and it is 134.9 million yen or 
1.08 billion dollars. 
 
Table 3:Summary Statistics 
  Average  Std. Dev.  Minimum  Maximum 
Shot Rate(%)  29.6695  6.067872  18.4074  45 
Copayment (yen)  1171.429  427.618  1000  2200 
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Table 4 : Estimation Result 
Explanatory Variable  Estimator p-value  Estimator p-value  Estimator  p-value 
Copayment  -0.0066561 0.002         
Shot Rate(Instrument)      -0.0006669 0.304  -0.0027877  0.034 
'02/'03 Season  8.757308 0.000  0.0112177 0.088  0.0295542  0.015 
Sendai  1.208579 0.727  -0.0047122 0.500  -0.0021133  0.780 
Chiba  5.458579 0.153  0.0057438 0.475  0.0173561  0.141 
Tokyo  -1.674325 0.300  0.0023957 0.727  -0.0144918  0.090 
Yokohama  -0.6914208 0.781  -0.0021031 0.682  -0.0035337  0.464 
Kawasaki  -5.184099 0.123  0.0056449 0.442  -0.0053089  0.455 
Nagoya  -3.341421 0.222  0.0034983 0.561  -0.0035525  0.502 
Kyoto  -4.723365 0.113  0.0073267 0.297  -0.0026762  0.680 
Osaka  -4.441422 0.095  0.012161 0.065  0.0027774  0.618 
Kobe  -4.691421 0.117  0.0034541 0.614  -0.0064597  0.325 
Hiroshima  4.058578 0.225  0.0061583 0.394  0.0148015  0.141 
Kitakyuushuu  -5.79142  0.076  0.0122467 0.137  0.0263081  0.548 
Fukuoka  -2.991421 0.350  0.0009681 0.883  -0.0053403  0.376 
Constant  34.46885  0.000  0.0437944 0.030  0.1028622  0.005 
Sample Size  28  26  26 
F statistics  10.81  2.53  2.60 
p-value for F statistics  0.0001  0.0639  0.0537 
  0.8357  0.4622  0.4548 
Note: Coefficients for '02/'03 Season indicate the structural difference of it from '01/'02 Season keeping 
constant all other aspects. Positive coefficient means that the average  is larger in '02/'03 season 
than in '01/'02 season if the situation which is represented by figure  of explanatory variables are 
the same in both season. 
 
      Following the similar way, we can calculate its BCR easily, i.e. 
.0028(-1000)(-.007) 6 million yen / (2000/12000)
                     -1000(-.007)4500yen   = 22.4  (11) 
where 2000/12000 in the numerator is the adjustment factor for the elderly because the potential   
population of the numerator is the whole population but    the counterpart in the denominator is 
the population of the elderly. Moreover its 95% confidence interval is calculated as [2.2,43.7] 
and we can confirm that this BCR is significantly greater than 1. 
 
R
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V.1.4.  Discussion 
 
 (1)  Evaluation  of  Estimation  Results 
 
   From Table 3, showing the average shot rate and average copayment, we can see that the 
price elasticity of shot rate is -0.2606. It appears to be higher than the results of the previous 
study.  That is, the study based on the conjoint analysis which is the most reliable technique 
with a hypothetical questionnaire indicates -0.02 to -0.04 for the elasticity, and the actual 
behavior in the '01/'02season indicates -0.1 for the elasticity[4]. Hence, the result in this paper 
shows that the shot rate is very elastic against price. 
   There are two main reasons for these differences. Firstly, this study focus on the 
metropolitan and big cities and so it may be biased toward extremely urban areas, whereas the 
previous studies cover the whole of Japan. If the residents in the urban areas have higher price 
elasticity to vaccination than rural areas, our results here may be reasonable. In this sense, the 
previous studies seem to be more general than this research. 
   Conversely, the data in this paper covers all residents in an area, while the previous study 
relied on survey by mail and it did not cover all the residents, of course, and they may not be 
representative. If the respondents of the questionnaire tend to have inclination toward 
vaccination for influenza compared with non-respondents, the shot rate may be insensitive to 
price. In this sense, the result in this study seems to be more reliable than the previous one. 
Though, it is not certain which estimate and reasoning is more reasonable, We have to remind 
ourselves that our final goal, namely the analysis with the BCR, is independent of price elasticity 
of shots as explained before. 
   On the other hand, the shot rate elasticity of mortality rate is -2.48, and thus mortality is 
elastic against shot rate. Combining these two estimation results, if copayment would be cut by 
a thousand yen (eight dollars), it raises the shot rate by 7 percentage points, and reduces the 
mortality rate due to pneumonia and influenza by .029 percentage point. It seems like a very 
small number, but since the average mortality rate due to pneumonia and influenza is very small, 
the effect certainly is quite high. In fact, this means this policy can reduce about 423 death in an 
average big city. 
   S i n c e  F statistics in the first equation is higher than ten, the fitted variables seems to be 
good instrument[5]. In other words, the reason of insignificance of the shot rate in the crude 
weighted least square can be inferred as positive simultaneous bias which offsets the shot rate 
effect on the mortality rate. Therefore, the instrument variable can solve this bias and it is a 
more appropriate method for this problem. 
 64  Y. Ohkusa, T. Sugawara / Public Policy Review 
 (2)  Evaluation  for  BCR 
 
   The obtained BCR, 22.4, is quite high compared with the other countries or other 
vaccinations. In some other countries, since it is 1.93[6] for children before school and 1.81[7] or 
2.92[8] for healthy adults, the obtained IBCR is much higher. Compared with other diseases, it 
is 2.5[9] for measles in Japan and it is just 1.4[10] in the case of hepatics B for all infants in 
China where there are epidemic areas. Overall, the policy of subsidy for shots for the elderly is 
quite cost-effective and there is concrete evidence for this. 
 
  (3)    Problem and limitation in this analysis 
 
      At first, there are some differences in the definition of population among areas for the policy 
targeting or/and for the shot rate calculation. Especially, this policy also subsidizes the 
non-elderly, i.e. between 60 and 64 years old, who have heart, kidney, and respiratory problem 
or HIV career. Moreover, each city sometimes extend the target population more than the 
national policy requirement. Typically, some cities subsidize the institutionalized elderly even if 
they are younger than 65. These additional target populations are included in the denominator in 
some cities, but are not in other cities. The subsidized number in the numerator of the shot rate 
include such additional targeting populations, and thus the shot rate may be different depending 
on whether the denominator include such additional targeting populations or not. However, 
these additional target populations are quite small compared with the elderly, and it is less than 
just one percent. Therefore, such an inconsistency in the denominator of the shot rate may not 
substantially affect the result. 
   Moreover, the starting date of subsidy is not the same among areas. In particular, it is 
remarkable in the first season of this policy, i.e. the '01/'02 season. Our data of shot rate only 
includes those who received the subsidy, and does not include those who did not receive subsidy 
but received shots. So the shot rate may be lower than the actual rate in the area where the 
starting date of subsidy was delayed. In this sense, the data of shot rate is always lower than the 
actual shot rate among the elderly. This measurement error may lead to upper bias of the 
estimated coefficient of the shot rate in the second estimation. Hence, it also lead upper bias in 
IBCR. However, it is not sure how many elderly people received a shot but were not subsidized, 
and so we cannot evaluate this effect in detail. 
      On the other hand, it is questionable whether our sample in the metropolitan and big cities 
represents the whole of Japan or not. The coverage of the elderly population in our data is 21% of 
Japan, but it may not be the average population. Especially, there may be big differences from 
those in the rural areas as mentioned before. So as to check the robustness of the obtained result, 
we should extend our analysis to the other areas. 
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mortality which is defined by the difference between the actual number of deaths and the 
hypothetical number in the case of no influenza epidemic[11-14]. Therefore, we have to replace 
the mortality definition from the crude number of death to the excess mortality. In particular, 
excess death should be defined regardless of the cause of death[14] because it is very well known 
that the influenza epidemic raises the mortality rate from other causes than pneumonia or 
influenza and these death can be prevented by the vaccination and control of the influenza 
epidemic. Moreover, if we can limit the number of deaths to those of more than 65 years old, it 
would be a more precise measure. In this sense, the excess mortality of those older than 65 years 
old in all causes of death is the best measure to evaluate the vaccination effect. 
   At the same time, we also need more explanatory variables which affect the shot rate or 
mortality. For example, the hortative measure for vaccination may be much different among local 
governments and it may affect the shot rate. Even in this case, if such a measure did not change 
in an area in the two season, this effect can be controlled out completely by the area dummies 
and it does not affect the estimated coefficient. 
      On the other hand, there are many implicit assumptions in BCR. First of all, since we limit 
the effect of vaccination to the prevention of death, and thus it is certainly a finer measurement 
than the prevention of the severe conditions like hospitalization as emphasized. Since it is 
difficult to obtain the data of the number of patients and the hospitalized, these numbers would 
be based on the similar estimation. Hence, these are far less precise than the number of death. In 
other words, we choose preciseness rather than broadness in the definition of effectiveness. 
Obviously, this limitation lower BCR. If we take the effects of vaccination on the number of 
patients and the hospitalized into consideration, BCR definitely becomes higher than the BCR 
discussed in this paper. It strengthens our conclusion in favor of the subsidy and has never 
change it. 
      Conversely, the ignorance of opportunity cost for vaccination or side effects certainly raises 
BCR. However, almost all of them are retired, and suffered from chronic disease and thus they 
usually visit a doctor, their additional opportunity cost for vaccination seems to be small. 
Concerning side effects, on 28 August, 2003, the Ministry of health and welfare reported only 
two fatal cases and 18 severe side effects from 1998 to 2003. Therefore, we can safely ignore these 
cost and the obtained conclusion is probably not affected by the introduction of these costs. 
   Finally, we can extend the effectiveness of vaccination to the number of patients or the 
medical cost. The data limitations of these variables are already mentioned. Moreover, since the 
primary purpose of vaccination is the prevention of severe cases, if we extend to these aspects, 
the results may not be clear and BCR may decline. In extreme case, the fatal case may use less 
medical resources compared with severe cases where the patients survives. In this sense, the 
limitation of effectiveness on the number of deaths seems to be more appropriate for considering 
the vaccination policy. Nevertheless, the research on the number of patients and medical cost are 
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V.2.    Example 2: Smoking Cessation Program 
 
   W e  s h o w  ex ante policy evaluation for smoking cessation program as another example of 
cost-effectiveness analysis in policy for medicine or public health which is originally in Ohkusa 
and Sugawara(2005a). 
 
V.2.1.  Objective 
 
   There are many programs to cease smoking, such as group therapy, individual therapy by 
professional staff such as medical doctors or nicotine replacement therapy. The Tobacco Use and 
Dependence Clinical Guideline Panel, Staff, and Consortium Representatives (2000) recommend 
the use of nicotine replacement therapy for nicotine dependence. In Japan, nicotine replacement 
therapy uses nicotine patch or nicotine gum, but the former requires a prescription written by a 
medical doctor. The later does not require it and we can buy it as an OTC (Over-the-counter) 
drug at any pharmacy without consultation by medical doctors. The Nicotine patch is used in 
more than 60 countries, and is an OTC in more than 30 countries. However, it has not switched 
to the OTC, yet in Japan. On the other hand, individual consultation by a medical doctor is not 
covered by health insurance in Japan. 
   This paper tries to conduct an ex ante cost effective analysis to evaluate new policies for 
smoking cessation, such as switching the nicotine patch to OTC (PO) and insurance coverage 
for individual therapy by medical doctors (PI). 
 
V.2.2.  Material  and  Method 
 
     The survey collected information through the web site in December 2004. The respondents 
were limited to smokers aged 20 to 59, and randomly drawn stratified are, age, and gender which 
replicate the national average from the list of the contracted members with the survey company.   
      It employs the hypothetical questionnaire which is used in the Conjoint analysis ( Halpern, 
Berns and Israni(2004), Ratcliffe, Buxton, McGarry, Sheldon and Chancellor(2004), Maddala, 
Phillips and Johnson(2003) Schwappach(2003), Phillips, Maddala and Johnson(2002), 
Gyrd-Hansen and Slothuus(2002), Aristides, Chen, Schulz, Williamson, Clarke and 
Grant(2002), Bryan, Roberts, Heginbotham and McCallum(2002), Ratcliffe, Van Haselen, 
Buxton, Hardy, Colehan and Partridge(2002), Telser and Zweifel(2002), Gabriel, leung, Chan, 
Chau and Chua(2001), Johnson, Banzhaf and Desvousges(2000), Ratcliffe(2000), Tilley and 
Chambers(2000)). It asks the respondent to choose visiting a doctor or going to a pharmacy 
under the hypothetical situations: about cost of medical services and OTC, traveling time to 
visit a doctor, insurance coverage of individual consultation by a medical doctor, and 
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In each attribute, the levels are set as follows; traveling time to visit a doctor: 30 minutes, 60 
minutes, and 120 minutes, cost for both medical service and OTC: 100 thousand yen (800 
dollars) to 500 thousand yen (4000 dollars) by 100 thousand yen (800 dollars), explanation by 
pharmacist: none, 5 minutes and 10 minutes, insurance coverage and switching to OTC: yes or 
no. 
      In the case of insurance coverage for medical service, costs for medical services are reduced 
to be 30%, which is the coinsurance rate in Japan. The Cost for medical services and OTC are 
selected from estimations of cost in the current situation. Expected rate of those who quit 
smoking is supposed to be the same among programs. 
      Hence there are 900 possible scenarios. Of these, we select 50 scenarios orthogonally. Then 
we allocate 10 questions to each respondent and set 5 patterns. 
   We adopt random effects Probit model which is very common to estimate the Conjoint 
analysis. Especially, we estimate it separately, whether nicotine patch is switched or not, so as 
to fully evaluate its effect. In each estimation, the dependent variable is binary; if i th the 
individual choose OTC for j ( j=1,2,…,10) th question, then Oi,t=1, and is zero otherwise. The 
estimation equation is 
ε µ α α α α α α α j , i i j , i E j , i E j , i C j , i I j , i T j , i M
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where  Mi,j, T i,j, I i,j,  Ci,j,  E j , i
5 ,  E j , i
10  are respectively the cost for medical service, the traveling 
time to visit a doctor, dummy for insurance coverage, the cost for OTC, dummy for a five minute 
explanation by a pharmacist, and dummy for a ten minute explanation by pharmacist. µi is the 
random effect that captures individual effects and εi,j is a stochastic disturbance term. 
      Next, we perform a cost effective analysis of these two new policies, PO and PI, based on the 
estimated demand curve. We calculate the incremental benefit cost ratio (IBCR) with and 
without such an externality among the current situation and switching the nicotine patch to 
OTC, insurance coverage for smoking cessation therapy by a doctor, and both of them. Moreover, 
we refer to net benefit in this policy so as to evaluate its amount of gain or loss in monetary 
term. 
 
V.2.3.  Results 
 
   We collected information from 2,839 individuals and the response rate was 51.9%. The 
estimation results are summarized in Table 5. It shows that all coefficients are significant and 
the variance of the random effect is significantly more than zero. Therefore, its consideration is 
important.  
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Table 5 :Demand for OTC and Medical Services which Assists Quit Smoking 
 Nicotine  Patch  Nicotine  Gum 
 Marginal  Effect p value  Marginal Effect p value 
Medical Cost(log)  0.09595611  .000  0.23414278  .000 
Traveling Time(log)  0.08233906  .002  0.09190193  .000 
Insurance Coverage  -0.06234507  .021  -0.03687187  .001 
OTC Cost(log)  -0.33815518  .000  -0.23327342  .000 
Explanation(5 min.)
a)  0.09684908  .000  0.01804711  .089 
Explanation(10 min.)
a) 0.07527379  .050  0.08756433  .000 
# of sample  4725  7066 
# of individuals  2375  2377 
p-value for  χ
2 test
b)  <0.0000  <0.0000 
Log Likelihood  -1531.5  -3187.5 
p-value forχ
2 test
c)  <0.0000  <0.0000 
Note:Dependent variable is binary variable whether they demand for OTC (nicotine patch or nicotine  
gum) or not.
a):"Explanation (5 min.)" and "Explanation (10 min.)" means that how long pharmacist 
explain about nicotine gum or patch when the consumer buy it at pharmacy.
b): Likelihood ratio test 
for estimation model against constant term only.
c): Likelihood ratio test for estimation model against   
the model without random effects. 
 
   The disease burden of smoking has been estimated as 3.7 to 7.3 trillion yen (Institute of 
Health Economics and Planning(1997), Ohkusa and Sugawara(2005b)). In this amount, 
externality is the insurance paid for the medical cost of treatment for smoking related disease. 
While it is not recognized as costs for smokers, it is actually the cost from the societal view 
point. Such externality is estimated as 0.88 to 1.12 trillion yen and rate of externality is 
estimated as 7.3/(7.3-1.12)-1=0.18.  
      The result of cost effective analysis is summarized in Table 6. It shows the results separately 
in terms of the externality considered. The first row indicates the case of switching nicotine 
patch to OTC. The second row presents the result of the case where the therapy by doctors does 
not become popular while it is covered by insurance, and where the traveling time is ninety 
minutes .The third and fourth rows summarize the result if the traveling time is reduced to be 60 
or 30 minutes. Besides, the result if both PO and PI are implemented by traveling time is also 
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Table 6:IBCR of Switching to OTC of Nicotine Patch and/or Insurance Coverage for Quit 
Smoking Therapy   
without Externality  with Externality 








Median Lower Upper Median Lower Upper 
Yes No 90  1.46  1.39  1.53  1.72  1.65  1.81 
No Yes  90  0.189  0.039  0.295  0.203  0.024  0.329 
No Yes  60  0.311  0.208  0.386  0.352  0.229  0.442 
No Yes  40  0.461  0.398  0.509  0.534  0.460  0.591 
Yes Yes 90  0.789  0.733  0.863  0.910  0.840  1.00 
Yes Yes 60  0.711  0.698  0.749  0.819  0.803  0.867 
Yes Yes 30  0.665  0.576  0.734  0.767  0.661  0.850 
 
 
Table 7:Net Benefit of Switching to OTC of Nicotine Patch and/or Insurance Coverage for Quit 
Smoking Therapy by Doctor   
After Switching  Before Switching  Insurance 
Coverage 
Traveling 
Time  OTC  Medical Service OTC  Medical Service 
without 
Externality 
         
No  90  1321.0425  32.014884  193.39717  21.691252 
    [929.8,1805]  [31.72,32.27]  [145.8,252.9]  [21.46,21.92] 
        
Yes  90  179.66613  -211.5101  1.8866509  -712.20123 
    [103.9,207.5]  [-223.9,-198.7] [1.193,.9411]  [-718.5,-705.7] 
        
Yes  60  111.0619  -214.41094  0.94754236  -839.76731 
    [61.72,191.2]  [-230.9,-197.6] [.5874,1.507]  [-848.4,-830.8] 
        
Yes  30  44.870128  -260.64714  0.27154143  -1013.9675 
    [23.23,82.75]  [-288.6,-232.6] [.1625,.4476]  [-1028,-999.5] 
              
with 
Externality 
          
No  90  2073.351  47.488069  303.77122  36.81772 
    [1511,2744]  [47.23,47.69]  [231.9,392.5]  [36.55,37.07] 
        
Yes  90  340.16637  -114.27436  3.4450426  -571.11183 
    [206.1,538.4]  [-128.1,-100.0] [2.217,5.282]  [-578.3,-563.7] 
        
Yes  60  218.27756  -106.47282  1.7637574  -654.23084 
    [127.2,358.7]  [-125.9,-86.70] [1.112,2.7599] [-664.1,-644.0] 
        
Yes  30  94.090628  -9.1588703  0.52249262  -731.27581 
    [51.14,165.4]  [-39.45,20.92] [.3182,.8465]  [-747.5,-714.6] 
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   These tables show obviously that the IBCR for PO exceeds one significantly and is 1.46 
without externality, and is 1.72 with externality. The net benefit achieves 135 billion yen and it 
is higher than the current net benefit of 21 billion yen by more than 100 billion yen. 
      Conversely, the IBCR for PI is less than one, and thus it does not support the 
implementation of this reform. This policy reduces the net benefit in the OTC market to less 
than 0.2 billion yen due to the reduction in copayment by insurance coverage and the society 
loses 71.2 billion yen.   
      Moreover, if the number of medical institutions which provide smoking cessation therapy by 
doctors increases and traveling time is shortened to be 60 or 30 minutes, the net benefit in the 
OTC market is reduced to 30 million yen and the net loss in the market for medical service 
achieve more than 100 billion yen. Even if we take such an externality into consideration, it 
leads the negative net benefit amounts to 57 billion yen in the society as a whole. When we test 
PO and PI simultaneously, its IBCR is not larger than one significantly, even though the upper 
limit of a case reaches one. 
 
V.2.4.  Discussion 
 
      If we can assume that the expected benefit of quitting smoking is the same among smokers, 
the demand curve represents the subjective quit rate. In other words, the smokers who join the 
smoking cessation program are thought to have a higher subjective quit rate or have more 
aptitude of these programs than other smokers, those who do not join the program under the 
same price. 
      Conversely, almost all the cost effective analyses so far are usually based on the assumption 
of average individual or some artificial scenarios. Namely, the quit rate is assumed to be a 
certain level in all smokers in this case. It is true if we consider some nonexclusive public goods 
because the word "join" or "not join" does not make any sense. However it must not be true if we 
consider the private goods. In this sense, immunization, medical services or OTC drugs are 
exclusive private goods. 
   Even though there is heterogeneity among individuals, these studies ignore this clear fact 
and assume that they are homogenous. In our context, these typical cost effective analyses 
ignore the difference in the subjective quit rates which are represented by the demand curve for 
the smoking cessation program.   
   Especially, when we evaluate the policy with some subsidies including health insurance 
coverage, it is very important to recognized that such a policy enforces joining the programs 
whose subjected benefit is lower than those who join the program even though such a policy is 
not implemented. In other words, the average benefit among participants must be decreased by 
such a policy. It is very well known as a deadweight loss. Needless to say, such a policy for 
private goods must not be recommended because it worsens the welfare. Therefore the cost   Y. Ohkusa, T. Sugawara / Public Policy Review 71 
effective analysis must be based on the demand curve if we consider the policy for private goods, 
or the analysis leads to the wrong conclusion. 
   Moreover, almost all the cost effective analyses so far usually fail to consider externalities. 
As explained above, the cost effective analyses so far have been based on the average or 
hypothetical individual and summing them up into the aggregate benefit and cost. Hence the 
externality which does not count at the individual level may be ignored. This externality does 
not seem essential in the cost effective analyses and thus it can be incorporated in the analysis, 
but typically it is ignored. 
   On the other hand, we can easily take such an externality into consideration which is 
represented by the deviation of social benefit from the demand curve. This deviation is the only 
reasons for policy intervention. In the case of positive externality, since the deviation of social 
benefit other than individual's utility, the deadweight loss induced by the policy may be 
compensated. Hence, cost effectiveness analysis for private goods is not for considering whether 
such a positive externality is sufficiently large enough to compensate the deadweight loss. 
Therefore, externality is the most important and essential of cost effective analysis for private 
goods. 
      In our context, PI means to provide subsidy of 70% of the medical cost and thus it leads to 
some deadweight loss. Therefore, it needs some evidence that its externality is larger than the 
deadweight loss. On the other hand, switching the nicotine patch to OTC is a kind of 
deregulation and thus it does not lead to deadweight loss.   
      Table 6 and 7 imply that PI does not have evidence but PO has it to support implementation. 
The point to evaluate PI is whether the externality is so large that this deadweight loss can be 
compensated. Unfortunately, it cannot. Even if we perform PO and PI simultaneously, though 
the nicotine patch as OTC partially offset the demand for medical services, this strategy also 
does not have evidence to support implementation. Therefore we can conclude that PO is 
strongly recommended but PI is not. 
      If we calculate IBCR without using a demand curve, but assuming average individual even if 
a new policy is implemented, it should be as follows: Assume the quit rate is 30% in any program, 
PO and PI, and cost in both policies is 30 thousand yen (240 dollars), then the additional cost to 
quit per person is 70 thousand yen (560 dollars). On the other hand, the benefit of quitting 
smoking is supposed to be 3.7 to 7.3 as mentioned before, and its per capita term is 185-365 
thousand yen (1.48-2.92 thousand dollars) if the smoking population is 20 million. We note that 
this number does not depend on how many person attend due to the new policy. Therefore IBCR 
is 2.6429(=185/70)- 5.2143(365/70).   
      Even though this extremely simple calculation ignores discounting, it does not seem to affect 
the its implication. It is clearly more than one, so this very simple calculation recommends the 
implementation of both PI and PO. However, we prove that PI make huge deadweight loss and 
externality cannot compensate it fully, so we cannot recommend it. This small example explain 72  Y. Ohkusa, T. Sugawara / Public Policy Review 
how such a simple cost effective analysis leads to a wrong conclusion. 
   However, we have some limitations. The most important of all would be environmental 
tobacco smoking (ETS). It must raise positive externality of quitting smoking. Even though its 
medical cost is very small compared with the medical costs of smokers, the bad smell of smoke 
worsen the QOL of non-smokers. Insurance coverage for smoking cessation therapy by doctors 
may be changed to be cost effective. Accumulation of knowledge about ETS in epidemiology and 
health economics is necessary as soon as possible so as to evaluate smoking cessation programs. 
 
VI.  Conclusion 
 
   As  mentioned  before, 
      In other countries, the smoking policy is based on the result of cost effectiveness analysis in 
the fiel d of poli cy eva l ua ti on for m edi ci ne or publ ic hea l th. The  m ore  re sponsibili ty  wil l be 
required for policy makers to explain for all citizens about the process of political decision they 
made. Taking this situation into consideration, additional research and discussion should be 
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